CPIC: The Clinical Pharmacogenetics Implementation Consortium

CPIC is the group behind many of the dosing recommendations printed on a pharmacogenomic report. This article explains what the consortium does, then adds a practical guide to how its guidelines are graded, how your metabolizer status is decided and how to use the results with your prescriber.

In today’s rapidly evolving healthcare environment, personalised medicine is becoming increasingly important. One of the most crucial advancements in this area is the implementation of pharmacogenetics, the study of how genetic variations affect an individual’s response to drugs. To facilitate the practical application of pharmacogenetics in clinical settings, the Clinical Pharmacogenetics Implementation Consortium (CPIC) was established. This blog explores the role of CPIC, its significance in personalised medicine, and how it is changing the landscape of patient care.

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium is a global initiative designed to help healthcare providers make better decisions about drug therapies based on patients’ genetic profiles. Its guidelines provide evidence-based recommendations on how to use genetic information to guide drug therapy, improving drug efficacy and minimising adverse drug reactions.

Founded in 2009, CPIC is an organisation consisting of international experts in pharmacogenetics, pharmacology, and clinical practice. Their main goal is to bridge the gap between research and real-world clinical practice, ensuring that pharmacogenetic testing becomes an integral part of patient care.

The Importance of Pharmacogenetics

Pharmacogenetics plays a pivotal role in optimising drug therapy, as individuals may respond differently to the same medication. Some people may experience effective treatment with a specific drug, while others may face severe side effects or have little therapeutic response. Genetic variations, such as mutations in drug-metabolising enzymes, can alter how a drug is absorbed, distributed, metabolised, or eliminated from the body. This results in variability in treatment outcomes.

How are CPIC Guidelines Developed?

CPIC guidelines are created through an extensive evidence-based review process. Experts from various fields, including pharmacology, genetics, and clinical practice, collaborate to evaluate scientific literature, analyse clinical data, and determine the strength of evidence supporting pharmacogenetic testing for particular drugs.

This thorough evaluation leads to the development of standardised recommendations on:

• When should pharmacogenetic testing be considered
• How genetic test results should influence drug selection and dosage
• Alternative therapeutic strategies when genetic data indicates potential risks

Key Points about CPIC Guidelines

• Standardized formats
• Systematic review of literature
• Grading of evidence and recommendations
• Peer reviewed
• Freely available
• Updated
• Authorship with COI policy
• Closely follow IOM practices
• Endorsed by professional societies (ASHP, ASCPT) and supported by CAP
• Cited as practice guidelines in PubMed and in the NIH’s Genetic Test Registry (GTR) for clinical pharmacogenetic tests

CPIC guideline genes and drugs

CPIC guidelines now cover more than 20 genes and well over 50 drugs, and new guidelines are added as evidence grows. Examples by specialty are listed below.

CPIC Guidelines apply to a Variety of Disciplines

Oncology (Cancer Treatment):

Drugs: “Chemotherapy” medicines like 5-fluorouracil, Irinotecan and mercaptopurine.

CPIC Impact: Genotypes within genes like DPYD (5-FU metabolism) and UGT1A1 (irinotecan metabolism) help in treatment decisions that lower toxicities and improve efficacy.

Cardiology:

Drugs: include Warfarin, beta-blockers, statins, clopidogrel, and antiarrhythmic drugs.

Impact: Changes in genes like VKORC1, CYP2C9, CYP2C19, and SLCO1B1 influence the anticoagulation treatment, statin dosage, and vulnerability to blood thinners, such as Clopidogrel. Genotyping could help prevent bleeding complications or failing therapy.
Psychiatry:

Drugs: Antidepressants and opioids, antipsychotics, as well as sedatives (many of them, such as SSRIs and tricyclic antidepressants, broken down by CYP2D6 or CYP2C19).

Impact: Pharmacogenetic tests may help determine the choice of medication for anxiety, depression, and psychosis. Different versions of CYP2D6 and CYP2C19, for example, alter the metabolism of many psychotropic medications, resulting in impacts on efficacy as well as negative side effects.

Neurology (Pain Management and Epilepsy):

Drugs: Carbamazepine, phenytoin, valproate, opioids.

Effect: In the case of epilepsy, HLA-B*15:02 testing is necessary before prescribing carbamazepine. This is to ensure that there are no dangerous skin reactions. CYP2D6 as well as CYP2C9 polymorphisms can also impact the treatment of opioids and anti-epileptic medications.

Infectious Diseases:

Drugs: Abacavir, voriconazole, antibiotics.

Impact: Treating HIV with the HLA B*57:01 allele can put patients at risk of hypersensitivity reactions to Abacavir. For antifungals like voriconazole, CYP2C19 genotyping helps decide whether voriconazole or an alternative antifungal is the better choice.

Transplant Medicine:

Drugs: Tacrolimus or Cyclosporine (immunosuppressive drugs).

CPIC Effect: CYP3A5 variants can affect the metabolism of tacrolimus and the dosing of the drug is altered to stop toxicity and rejection of organs among transplant recipients.

Endocrinology:

Drugs: Sulfonylureas such as glipizide and glyburide.

Impact: There are no CPIC guidelines for thyroid medicines, glucocorticoids or insulin. Sulfonylureas are broken down by CYP2C9, and their FDA labels warn that people with G6PD deficiency can develop hemolytic anemia, so both genes can be relevant.

Hematology:

Drugs: Thiopurines (azathioprine, mercaptopurine) and fluoropyrimidines (fluorouracil, capecitabine).

Impact: TPMT and NUDT15 testing can help steer thiopurine dosing away from severe bone marrow suppression, and DPYD testing before fluorouracil or capecitabine can prevent severe toxicity.

Rheumatology:

Drugs: Azathioprine and allopurinol.

Effect: TPMT and NUDT15 guide azathioprine dosing in autoimmune conditions, and HLA-B*58:01 testing identifies people at higher risk of severe skin reactions to allopurinol. There are no CPIC guidelines for methotrexate or TNF inhibitors.

Obstetrics and Gynaecology:

Drugs: Antidepressants and pain medications used around pregnancy.

Effect: There are no CPIC guidelines for oral contraceptives or hormone therapy. Results are still useful for other medications, such as SSRIs or codeine-type pain relievers, that may be considered before or after pregnancy.

Pediatrics:

Drugs: Ivacaftor for cystic fibrosis, aminoglycoside antibiotics and ondansetron.

Impact: CPIC guidance covers ivacaftor, which works for people with specific CFTR variants, aminoglycosides, which carry a hearing loss risk for people with certain MT-RNR1 variants, and ondansetron, which is guided by CYP2D6. It can also help in reducing the risk of adverse drug reactions.

CPIC’s Impact on Clinical Practice

CPIC has profoundly influenced the clinical practice by providing clear, practical recommendations that translate complicated genetic data into clinically clear decision-making. The CPIC guidelines address the most commonly prescribed medications including antidepressants pain medications, anticoagulants and anticancer medications.

For instance, the recommendations for medications like warfarin and clopidogrel codeine and selective serotonin-reuptake inhibitors (SSRIs) aid health professionals in determining the best dose or other medication based on genetic information. Patients thus receive greater therapeutic benefits, fewer negative side effects, and higher levels of satisfaction from their treatments.

Implementation Challenges and Solutions

There are a variety of issues that make the integration of tests for pharmacogenetics into clinical practice challenging:

• Education and Awareness: Many health professionals aren’t knowledgeable about the concept of pharmacogenetics. It is actively working to combat this problem by providing educational tools and training programs.
• Clinical Decision: Support Integrating genetic information in electronic medical documents (EHRs) and clinical practice is a challenge. CPIC collaborates with institutions to develop medical decision-support systems that flawlessly integrate genetic test results.
• Cost and reimbursement for testing could be considered to be expensive and reimbursement is an issue. However, the increasing evidence of cost-effectiveness as well as increased benefits for patients warrants the increased acceptance and insurance coverage.

The Future of CPIC and Pharmacogenetics

The promise of individualised medicine is largely dependent on the widespread use of pharmaceutical genetics. While research continues to improve, CPIC regularly updates current guidelines and offers guidelines for new drugs. Their aim remains clear: to make individual treatment the norm, not an exception.

Through the advancement of pharmacogenetic guidelines based on evidence, CPIC is defining healthcare’s future by providing better, safer treatments, and ultimately better treatment for patients across the world.

Who runs the Clinical Pharmacogenetics Implementation Consortium

The consortium was formed in 2009 as a shared project of PharmGKB and the Pharmacogenomics Research Network, with support from the US National Institutes of Health. Its members are volunteers: pharmacists, physicians, geneticists and scientists from many countries.

Each guideline is written by a separate author group that includes experts in the specific gene and drug. Authors disclose conflicts of interest, and drafts go through review before publication in a peer-reviewed journal.

The finished guidelines and supporting tables are free to read on the CPIC guidelines website. The same content is linked from PharmGKB, which curates the research behind them. Because everything is public, labs, hospitals and software companies can build the recommendations directly into reports and electronic health records.

How gene-drug pairs are ranked

Not every link between a gene and a medicine is strong enough to change a prescription. The consortium assigns gene-drug pairs a level that reflects how much evidence exists and whether a clear prescribing action is possible.

• Level A: strong evidence, and genetic information should be used to change prescribing.
• Level B: good evidence, and genetic information could be used to change prescribing because alternatives are about as effective and safe.
• Level C: evidence is mixed or weak, and there is no firm prescribing action.
• Level D: little evidence, and no prescribing action is recommended.

Full guidelines are written mainly for level A and B pairs. Within a guideline, each recommendation is also graded as strong, moderate or optional. That tells a prescriber how confident the authors are about the specific advice.

For you as a patient, the level explains why some findings on a report come with firm advice while others are listed for information only.

From DNA to metabolizer status

Each guideline follows the same three steps for almost every gene. Understanding them makes a pharmacogenomic report much easier to read.

1. Genotype. The lab identifies your two copies of the gene, written as star alleles such as CYP2C19*1/*2. Allele names come from PharmVar for many genes.
2. Phenotype. Standard tables translate the genotype into a metabolizer status, such as normal, intermediate or poor. For some genes, like CYP2D6, an activity score is added up first.
3. Recommendation. The guideline links each phenotype to prescribing advice for specific drugs.

The consortium also helped standardize the words labs use. Enzymes are described as ultrarapid, rapid, normal, intermediate or poor metabolizers. Transporters such as SLCO1B1 are described as increased, normal, decreased or poor function.

Your metabolizer status on paper can differ from how your body behaves if you take a drug that blocks the enzyme. This is called phenoconversion. Strong CYP2D6 inhibitors such as fluoxetine, paroxetine and bupropion can make a normal metabolizer act like a poor one. Our guide to CYP2D6 inhibitors explains more.

Well-known gene-drug pairs with published guidance

Some guideline recommendations are now widely used in hospitals and pharmacies. A few examples show the range:

• CYP2D6 with codeine and tramadol: these drugs must be converted to their active form. Poor metabolizers may get little pain relief, while ultrarapid metabolizers can build up too much active drug.
• CYP2C19 with clopidogrel: intermediate and poor metabolizers activate less of the drug and may get less protection after a stent.
• TPMT and NUDT15 with thiopurines: reduced function raises the risk of serious bone marrow toxicity with azathioprine or mercaptopurine.
• DPYD with fluorouracil and capecitabine: reduced DPD activity can cause severe toxicity from standard doses.
• SLCO1B1 with statins: decreased function raises the risk of muscle problems with simvastatin.
• CYP2C9 and VKORC1 with warfarin: results help estimate a starting dose.

You can see which medicines on the RPh Labs panel are linked to each gene on our medication list.

How CPIC compares with other pharmacogenetic guidelines

The consortium is not the only source of pharmacogenetic guidelines. Several groups work in parallel, and they usually agree on the main points.

• FDA drug labels. The FDA keeps a table of pharmacogenomic biomarkers in drug labeling. Some labels require or recommend testing; others simply mention the gene.
• The Dutch Pharmacogenetics Working Group (DPWG). A European group that publishes its own recommendations, often similar to CPIC advice.
• Professional societies. Specialty groups sometimes add gene testing to their own treatment guidelines.

When sources differ, it is usually on details such as the exact dose change or how strongly to recommend an alternative. PharmGKB lists the different recommendations side by side, which helps labs and prescribers see where they agree.

RPh Labs reports are updated when guidelines change, so your results stay current as the evidence grows.

What these guidelines do not tell you

The guidelines are written on a simple premise: the genetic result is already available. They explain how to use a result, but they generally do not decide who should be tested or when. That choice is left to prescribers, health systems and insurers.

A few other limits are worth knowing:

• They cover specific gene-drug pairs, not every medicine you might take.
• They do not replace clinical judgment. Age, kidney and liver function, other medicines, pregnancy and the condition being treated all still matter.
• They do not diagnose disease. A pharmacogenomic result says how you handle a drug, not whether you have an illness.
• They change as new evidence appears, so an older printed report may not reflect the latest advice.

Keeping these limits in mind helps you see each recommendation for what it is: a well-tested starting point for a conversation with your prescriber, not a final answer on its own.

Using guideline-based results with your prescriber

If your report shows a result with guideline advice for a drug you take, do not stop or change it yourself. Instead, share the report with your prescriber and pharmacist and ask how it applies to you.

Helpful questions include which of my current medicines are affected, whether my metabolizer status changes my dose or drug choice, and whether any of my other medicines could cause phenoconversion.

The RPh Labs at-home PGx test kit checks 20 genes from a cheek swab and reports them against more than 240 medications. Each report is reviewed by a PharmD pharmacist, a free pharmacist consultation is included, and prescribers can find more detail on our page for providers.

Conclusion

The Clinical Pharmacogenetics Implementation Consortium is a major participant in transferring pharmacogenetics information from labs of research to the patient bedside. Through providing guidelines based on evidence along with education, it allows healthcare providers to adapt treatments to the genetic information of patients, making treatments safer and more efficient.

The adoption of pharmacogenetics through CPIC guidelines is an important improvement in personalized medicine, which has the potential to lead to the future of personalized healthcare that is accessible to everyone.

CPIC frequently asked questions

What is CPIC?

CPIC (Clinical Pharmacogenetics Implementation Consortium) is an international association that develops guidelines based on scientific evidence to assist healthcare professionals in integrating the use of pharmacogenetic tests into their clinical practices for a more personalized treatment.

How can pharmacogenetics help patients’ health care?

Pharmacogenetics can help tailor treatment options according to the genetic makeup of an individual and improve the effectiveness of drugs while reducing the possibility of adverse side effects and adverse drug reactions.

What kind of drugs are listed within CPIC guidelines?

CPIC recommendations cover a vast spectrum of drugs that are used for the treatment of cancer as well as the management of pain, cardiovascular disease, mental health, and many more. The guidelines include recommendations on dosage and alternative medications that are based on genetic information.

Do I require a genetic test to follow CPIC guidelines?

Yes, it is advised when genetic influences could affect how someone reacts to certain drugs. CPIC guidelines guide clinicians to interpret the results of these tests to make informed choices.

Is pharmacogenetic testing costly?

While the expense of genetic testing is an issue, there are advantages of a personalized treatment over time, such as fewer adverse reactions and more efficient.

Is the consortium part of the FDA?

No. The Clinical Pharmacogenetics Implementation Consortium is an independent, volunteer-led group supported through the NIH-funded PharmGKB and research networks. The FDA works separately and lists pharmacogenomic information in drug labels. The two sources often agree, but they are not the same organization.

What does a level A rating mean for a gene and a drug?

Level A means the consortium judged the evidence strong enough that genetic information should be used to change prescribing, for example choosing a different drug or dose. Level B means it could be used. Levels C and D do not carry prescribing recommendations.

Can my metabolizer status change over time?

Your genes do not change, so your genetic metabolizer status stays the same for life. However, some medicines can temporarily change how an enzyme behaves, a process called phenoconversion. Your prescriber looks at both your genes and your current medicines.

Do CPIC recommendations apply to children?

Some do. Several guidelines, such as those for codeine, thiopurines and ondansetron, include notes about children. Others are based mainly on adult data. A pediatric prescriber will decide how a result applies to a specific child.

How can I tell if my report follows pharmacogenetic guidelines?

Look for references to the consortium, FDA labeling or DPWG on the report, or ask the lab. RPh Labs reports are reviewed by a PharmD pharmacist and updated when guidelines change, and you can book a free consultation to go through them.